Encompass Health Corporation
NYSE:EHCMedical - Care Facilities
-$1.95 today
- Market cap
- $13.24B
- Beta
- 0.59
- P/E (TTM)
- 15.9
- EPS (TTM)
- $6.14
- Dividend yield
- 0.76%
Volume 0.84M
Average 0.92M
EHC Sales of Investments
Cash received from selling or redeeming investments.
Encompass Health CorporationNYSE: EHC
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments declines year over year
Q2 FY2026 sales of investments of $16.7M fell 86.2% year over year, behind the -23.8% change in trailing-twelve-month sales of investments. Sequentially, it fell 61.1% from the prior quarter.
Context
- Sales of investments amounted to 2.9% of revenue in FY2025, up 2.6 pp from a year earlier.
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -86.2% toward the trailing-twelve-month pace of -23.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 172.8M USD
- Year-over-year change
- +814.3%
- 4-year CAGR
- +109.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 172.8M | +814.3% |
| FY2024 | 2024-12-31 | 18.9M | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (64.1M) | -812.2% |
| FY2021 | 2021-12-31 | 9M | — |
Sales of Investments vs competitors
How EHC compares with its peers on the latest reported figures
- EHC's LTM Jun 2026 sales of investments of $87.6M is the 2nd largest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of -23.8% is the 3rd highest of 5, against a peer median of +7.6%.
- Sales of investments amounts to 1.4% of revenue for EHC, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $91.14M | +51.0% | +90.8% | 1.7% | |
| LTM Jun 2026 | $87.6M | -23.8% | — | 1.4% | |
| LTM Sep 2026 | $30.73M | -60.0% | +13.4% | 1.9% | |
| LTM Jun 2026 | $19.91M | -35.8% | — | 0.4% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding EHC) | $0 | +7.6% | +52.1% | 0.0% | |
Competitors are the stored peer set for EHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 517.6M | 365.9M | 361.6M | 599.4M | 567.2M |
| Depreciation & Amortization | 219.6M | 243.6M | 273.9M | 299.6M | 327.9M |
| Deferred Income Tax | 17.4M | 27.9M | 3.9M | 10.7M | 22.3M |
| Stock-Based Compensation | 29.1M | 29.2M | 50.6M | 48.3M | 0 |
| Change in Working Capital | (118M) | (30.4M) | 50.3M | 21.9M | 4.3M |
| Accounts Receivables | (64.3M) | (16.9M) | (22.4M) | 3M | (15.2M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.9M | 2.3M | 11.8M | 3M | (22.6M) |
| Other Working Capital | (68.6M) | (15.8M) | 60.9M | 15.9M | 42.1M |
| Other Non-Cash Items | 50.1M | 69.6M | 110.5M | 22.9M | 253.9M |
| Operating Cash Flow | 715.8M | 705.8M | 850.8M | 1B | 1.18B |
| Capital Expenditures | (551.2M) | (584.1M) | (583.1M) | (642.5M) | (736.4M) |
| Acquisitions (Net) | (118.6M) | 64.1M | 0 | 0 | 0 |
| Purchases of Investments | (9M) | (35.2M) | (23M) | (22.5M) | (184.4M) |
| Sales of Investments | 9M | (64.1M) | 0 | 18.9M | 172.8M |
| Other Investing Activities | 3.5M | (7.7M) | 3.3M | (7.2M) | (14.8M) |
| Investing Cash Flow | (666.3M) | (627M) | (602.8M) | (653.3M) | (762.8M) |
| Debt Repayment | (59.1M) | (498.2M) | (83.3M) | (242M) | (29M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (14.6M) | (7.3M) | (8.2M) | (31.1M) | (158M) |
| Dividends Paid | (112.2M) | (99M) | (60.4M) | (62.8M) | (71.1M) |
| Other Financing Activities | (54.2M) | 458.8M | (45.3M) | 5.3M | (174.9M) |
| Financing Cash Flow | (240.1M) | (145.7M) | (197.2M) | (330.6M) | (433M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (190.6M) | (66.9M) | 50.8M | 18.9M | (20.2M) |
| Free Cash Flow | 164.6M | 121.7M | 267.7M | 360.3M | 439.2M |
Encompass Health Corporation
NYSE:EHC
Intrinsic Alpha fair value
Locked
Current Price
$134.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.